SecBot SecBot
EFFECT ·Filed May 7, 2026

VOR

Vor Biopharma Inc.
NEUTRAL
Impact 3/10
Horizondays Processed6mo ago SEC9999999995-26-001527
IPO/offering going effective
Actionable Insight • Neutral

The effectiveness is a procedural step with no direct financial impact on Vor Biopharma. Monitor for any subsequent prospectus supplements that could indicate accelerated selling by TCG Crossover Funds, which may create near-term overhang. The prior effective shelf from January 2026 covering 13.9M shares remains an additional overhang factor.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$16.08
T+0 close · May 7, 2026 · via day close
Latest settled
+33.15%
T+60 · $21.41
Vs SPY
+29.31%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 7 $16.08entry
  2. T+1 · 6mo ago +5.35%α +4.52% · $16.94
  3. T+5 · 6mo ago −1.06%α −2.56% · $15.91
  4. T+20 · 6mo ago −16.42%α −19.55% · $13.44
  5. T+60 · 4mo ago +33.15%α +29.31% · $21.41

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Vor Biopharma's S-3 registration statement (File No. 333-295346) became effective on May 6, 2026, enabling the resale of up to 5,338,078 shares of common stock held by TCG Crossover Funds from a March 2026 private placement. The company will not receive any proceeds from these sales. This is a routine registration rights fulfillment and does not represent new equity issuance or a capital raise for the company.

Key Facts

  • S-3 registration (File No. 333-295346) declared effective on May 6, 2026.
  • Registration covers 5,338,078 shares of common stock for resale by TCG Crossover Funds.
  • Shares were issued in a March 2026 private placement at $14.05 per share ($75M gross).
  • Vor Biopharma will not receive any proceeds from the resale.
  • This is a routine registration rights fulfillment, not a new capital raise.
  • The company has a prior S-3 effective from January 2026 covering 13,876,032 shares from a December 2025 private placement.

Financial Impact

No financial impact on Vor Biopharma; the company receives no proceeds from the resale.

Risk Factors

  • Potential near-term selling pressure if TCG Crossover Funds execute resales aggressively.
  • Combined overhang from two effective shelves (5.3M + 13.9M shares) could weigh on stock price.
  • No new capital raised for the company, limiting upside catalyst from this filing.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
85% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
EFFECT Filing (Primary)9999999995-26-001527
Document: 9999999995-26-001527-index.html9999999995-26-001527
Document: 9999999995-26-001527.txt9999999995-26-001527

Track record

17 reports on VOR

Performance horizon

3 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +70.35% at T+60 after the Jun 8, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $18.97 Now $18.97 −0.00% settles Nov 18
  2. Nov 12, 20264d ago 8-K Neutral 5/10 Entry $19.32 to $19.42 Now $18.97 −1.81% ▲ +0.52% +0.88% vs SPY
  3. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $18.66 to $19.88 Now $18.97 +1.66% ▲ +6.54% +6.23% vs SPY
  4. Oct 30, 202617d ago 424B5 Bearish 4/10 Entry $19.68 to $19.25 Now $18.97 +3.61% ▲ +2.19% +1.71% vs SPY
  5. Oct 30, 202617d ago Press Release Neutral 4/10 Entry $19.68 to $19.25 Now $18.97 −3.61% ▼ −2.19% −1.71% vs SPY
  6. Oct 22, 202625d ago Press Release Bullish 7/10 Entry $18.26 to $18.33 Now $18.97 +3.89% ▲ +0.38% −0.33% vs SPY
  7. Oct 5, 20266w ago Press Release Neutral 2/10 Entry $18.31 to $18.78 Now $18.97 +3.60% ▲ +2.57% +2.81% vs SPY
  8. Sep 29, 20266w ago Press Release Bullish 6/10 Entry $18.33 to $19.08 Now $18.97 +3.49% ▲ +4.09% +4.30% vs SPY
  9. Aug 11, 202613w ago Press Release Neutral 3/10 Entry $23.37 to $22.34 Now $18.97 −18.83% ▼ −4.41% −4.66% vs SPY
  10. Jul 9, 202618w ago 3 Neutral 2/10 Entry $19.14 to $18.03 Now $18.97 −0.89% ▼ −5.80% −5.03% vs SPY
Showing 10 of 17

US Market Status

Market Closed · Opens in 6h 43m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 7, 2026